Skip to contentB
Benitec Biopharma Inc.
B
BNTCBenitec Biopharma Inc. Q1 2024 · 10-Q
Revenue$0.00$0.00— vs Q1 2023 Net Income-$5.95M-$5.95MN/M vs Q1 2023 EPS Diluted-$3.05-$3.05N/M vs Q1 2023 Operating Income-$5,874,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Benitec Biopharma Inc. · CIK 1808898 · Engraved from SEC EDGAR
ended Sep 30, 2023 · filed Nov 13, 2023 · 44 d after period end